There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Collegium Pharmaceutical (COLL) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin Pharmaceutical, with a price target of $139.00. The company’s shares closed last Friday at $79.03, close to its 52-week low of $71.35.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 11.3% and a 46.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and Lexicon Pharmaceuticals.
BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $110.56.
See today’s analyst top recommended stocks >>
Collegium Pharmaceutical (COLL)
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical today and set a price target of $34.00. The company’s shares closed last Friday at $23.19.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 9.0% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Verrica Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $34.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
